KR102539030B1 - 드로스피레논을 포함하는 약학적 조성물 및 피임용 키트 - Google Patents

드로스피레논을 포함하는 약학적 조성물 및 피임용 키트 Download PDF

Info

Publication number
KR102539030B1
KR102539030B1 KR1020217002806A KR20217002806A KR102539030B1 KR 102539030 B1 KR102539030 B1 KR 102539030B1 KR 1020217002806 A KR1020217002806 A KR 1020217002806A KR 20217002806 A KR20217002806 A KR 20217002806A KR 102539030 B1 KR102539030 B1 KR 102539030B1
Authority
KR
South Korea
Prior art keywords
drospirenone
contraceptive
drsp
dosage unit
daily
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217002806A
Other languages
English (en)
Korean (ko)
Other versions
KR20210013663A (ko
Inventor
필립프 페린
조세 베라다
도미니크 드루앵
Original Assignee
라보라토리오스 레온 파르마 에스에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42671710&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102539030(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 라보라토리오스 레온 파르마 에스에이 filed Critical 라보라토리오스 레온 파르마 에스에이
Priority claimed from KR1020197017379A external-priority patent/KR102210982B1/ko
Publication of KR20210013663A publication Critical patent/KR20210013663A/ko
Application granted granted Critical
Publication of KR102539030B1 publication Critical patent/KR102539030B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020217002806A 2010-06-29 2011-06-28 드로스피레논을 포함하는 약학적 조성물 및 피임용 키트 Active KR102539030B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP10305708.9 2010-06-29
EP10305708 2010-06-29
US36839610P 2010-07-28 2010-07-28
US61/368,396 2010-07-28
KR1020197017379A KR102210982B1 (ko) 2010-06-29 2011-06-28 드로스피레논을 포함하는 약학적 조성물 및 피임용 키트
PCT/EP2011/060795 WO2012000981A1 (en) 2010-06-29 2011-06-28 Pharmaceutical composition comprising drospirenone and contraceptive kit

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197017379A Division KR102210982B1 (ko) 2010-06-29 2011-06-28 드로스피레논을 포함하는 약학적 조성물 및 피임용 키트

Publications (2)

Publication Number Publication Date
KR20210013663A KR20210013663A (ko) 2021-02-04
KR102539030B1 true KR102539030B1 (ko) 2023-05-31

Family

ID=42671710

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020137001350A Ceased KR20130048227A (ko) 2010-06-29 2011-06-28 드로스피레논을 포함하는 약학적 조성물 및 피임용 키트
KR1020217002806A Active KR102539030B1 (ko) 2010-06-29 2011-06-28 드로스피레논을 포함하는 약학적 조성물 및 피임용 키트
KR1020177019333A Active KR102164693B1 (ko) 2010-06-29 2011-06-28 드로스피레논을 포함하는 약학적 조성물 및 피임용 키트

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020137001350A Ceased KR20130048227A (ko) 2010-06-29 2011-06-28 드로스피레논을 포함하는 약학적 조성물 및 피임용 키트

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020177019333A Active KR102164693B1 (ko) 2010-06-29 2011-06-28 드로스피레논을 포함하는 약학적 조성물 및 피임용 키트

Country Status (25)

Country Link
US (9) US11452695B2 (enExample)
EP (3) EP4056186A1 (enExample)
JP (1) JP5810159B2 (enExample)
KR (3) KR20130048227A (enExample)
AR (1) AR081670A1 (enExample)
BR (1) BR112012033391B1 (enExample)
CA (3) CA2803721C (enExample)
CY (2) CY1122544T1 (enExample)
DK (1) DK3632448T3 (enExample)
EA (1) EA028680B1 (enExample)
ES (1) ES2908657T3 (enExample)
FR (2) FR20C1020I1 (enExample)
HR (1) HRP20220332T1 (enExample)
HU (3) HUE058176T2 (enExample)
LT (2) LT3632448T (enExample)
NO (2) NO2020015I1 (enExample)
NZ (1) NZ605176A (enExample)
PE (2) PE20130780A1 (enExample)
PH (1) PH12012502499A1 (enExample)
PL (2) PL3632448T3 (enExample)
PT (1) PT3632448T (enExample)
RS (2) RS59826B1 (enExample)
SI (2) SI3632448T1 (enExample)
SM (2) SMT202200129T1 (enExample)
WO (1) WO2012000981A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
NZ737948A (en) 2015-06-18 2023-03-31 Estetra Sprl Orodispersible dosage unit containing an estetrol component
LT3310345T (lt) 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
HUE054551T2 (hu) 2015-06-18 2021-09-28 Estetra Sprl Ösztetrolt tartalmazó, szájban diszpergálódó tabletta
KR102662025B1 (ko) 2015-06-18 2024-05-02 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 에스테트롤 성분을 함유하는 구강분해성 투여 단위
EP3108889A1 (en) 2015-06-23 2016-12-28 Philippe Perrin Drospirenone-based contraceptive for a female patient affected with excess weight
LT3313408T (lt) * 2015-06-23 2024-03-12 Laboratorios Leon Farma Sa Kontraceptikas drospirenono pagrindu, skirtas pacientėms, turinčioms antsvorio
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
EP4134082A1 (en) 2021-08-12 2023-02-15 Chemo Research, S.L. Method for treating endometriosis and providing effective contraception
WO2023152658A1 (en) 2022-02-10 2023-08-17 Lupin Limited Slow release drospirenone tablet composition
US20250186337A1 (en) 2022-03-01 2025-06-12 Chemo Research, S.L. Chewable oral contraceptive

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009138224A1 (en) * 2008-05-14 2009-11-19 Helm Ag Pharmaceutical composition comprising drospirenone

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652761C2 (de) 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE3022337A1 (de) 1980-06-11 1982-01-07 Schering Ag Berlin Und Bergkamen, 1000 Berlin Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen
JP3282731B2 (ja) 1990-06-15 2002-05-20 メルク エンド カムパニー インコーポレーテッド 結晶の構造および大きさを改良する結晶化方法
GB2256648B (en) 1991-05-29 1995-08-30 Colorcon Ltd Wax polish composition
DE19633685C1 (de) 1996-08-12 1997-10-09 Schering Ag Verfahren zur Herstellung von Drospirenon (6beta,7beta;15 beta,16beta-Dimethyl-en-3-oxo-17alpha-pregn-4-en-21,17-carbolacton, DRSP) sowie 7alpha-(3-Hydroxy-1-propyl)-6beta,7beta;15beta, 16beta-dimethylen-5beta-androstan-3beta,5,17beta-triol (ZK 92836) und 6beta,7beta;15beta,16beta-dimethylen-5beta-hydroxy-3-oxo-17alpha-androstan-21,17-carbolacton (90965) als Zwischenprodukte des Verfahrens
US6787531B1 (en) 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
RS50262B2 (sr) 1999-08-31 2018-10-31 Bayer Pharma AG Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva
US20020132801A1 (en) 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
KR100913910B1 (ko) 2000-01-18 2009-08-26 바이엘 쉐링 파마 악티엔게젤샤프트 호르몬 보충 요법용 드로스피렌온
US7786101B2 (en) 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
US20040087563A1 (en) 2002-11-05 2004-05-06 Siegfried Mayerhofer Hormone replacement therapy with cardiovascular protection using antialdosteronic progestins
MY142989A (en) 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
US20050220825A1 (en) 2004-03-10 2005-10-06 Adrian Funke Molecular dispersions of drospirenone
DE602005014227D1 (de) 2004-03-10 2009-06-10 Bayer Schering Pharma Ag Zusammensetzungen aus drospirenon in molekularer dispersion
MY151322A (en) 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
MXPA06014579A (es) 2004-07-07 2007-03-01 Wyeth Corp Regimenes de progestina ciclicos y equipos.
EP1625849A1 (en) 2004-08-09 2006-02-15 Liconsa, Liberacion Controlada de Sustancias Activas, S.A. Pharmaceutical composition comprising drospirenone and ethynylestradiol
ITMI20042338A1 (it) 2004-12-06 2005-03-06 Ind Chimica Srl Processo per la preparazione di drospirenone
US20060293295A1 (en) 2005-05-13 2006-12-28 Kai Strothmann Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl- (6S)-tetrahydrofolate
US8475838B2 (en) 2005-06-03 2013-07-02 Sandoz Ag Rapidly-dissolving pharmaceutical composition for inhibiting ovulation
TW200727920A (en) 2005-06-21 2007-08-01 Organon Nv New regimens for oral monophasic contraceptives
DE502005004948D1 (de) 2005-07-21 2008-09-18 Bayer Schering Pharma Ag Verfahren zur Herstellung von 3-Oxo-pregn-4-en-21,17-carbolactonen durch die metallfreie Oxidation von 17-(3-hydroxypropyl)-3,17-dihydroxyandrostanen
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
JP2010503632A (ja) * 2006-09-16 2010-02-04 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 経口改良放出製剤
AR066166A1 (es) 2007-09-21 2009-07-29 Organon Nv Sistema de suministro de droga
CA2714598A1 (en) 2008-02-13 2009-08-20 Bayer Schering Pharma Aktiengesellschaft Drug delivery system with stabilising effect
DE102008037025C5 (de) 2008-08-08 2016-07-07 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
TW201008569A (en) * 2008-08-08 2010-03-01 Bayer Schering Pharma Ag Progestin-containing drug delivery system
AR081670A1 (es) * 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009138224A1 (en) * 2008-05-14 2009-11-19 Helm Ag Pharmaceutical composition comprising drospirenone

Also Published As

Publication number Publication date
CA3003062C (en) 2019-12-31
PE20130780A1 (es) 2013-07-06
US20220339165A1 (en) 2022-10-27
RS63027B1 (sr) 2022-04-29
CA2803721A1 (en) 2012-01-05
FR20C1020I1 (fr) 2020-08-07
FR22C1031I1 (fr) 2022-09-09
US20230046871A1 (en) 2023-02-16
PL2588114T3 (pl) 2020-05-18
KR20210013663A (ko) 2021-02-04
AU2011273605A8 (en) 2016-07-28
US20220339106A1 (en) 2022-10-27
CA2803721C (en) 2018-06-12
KR20170085604A (ko) 2017-07-24
HUS2000016I1 (hu) 2020-07-28
LT3632448T (lt) 2022-03-25
JP2013529665A (ja) 2013-07-22
PT3632448T (pt) 2022-03-07
FR22C1031I2 (fr) 2023-12-22
US11504334B2 (en) 2022-11-22
US12280151B2 (en) 2025-04-22
US11951213B2 (en) 2024-04-09
ES2908657T3 (es) 2022-05-03
US20240366512A1 (en) 2024-11-07
LTPA2022513I1 (enExample) 2022-07-11
PH12012502499A1 (en) 2013-03-25
HRP20220332T1 (hr) 2022-05-13
US20250213487A1 (en) 2025-07-03
NZ605176A (en) 2015-02-27
US20220241209A1 (en) 2022-08-04
PL3632448T3 (pl) 2022-05-02
BR112012033391B1 (pt) 2020-02-27
EP2588114A1 (en) 2013-05-08
EP4056186A1 (en) 2022-09-14
PE20161410A1 (es) 2017-01-10
WO2012000981A1 (en) 2012-01-05
KR102164693B1 (ko) 2020-10-13
HUE058176T2 (hu) 2022-07-28
AR081670A1 (es) 2012-10-10
AU2011273605A1 (en) 2013-01-17
US11452695B2 (en) 2022-09-27
CA3003062A1 (en) 2012-01-05
HUS2200018I1 (hu) 2022-06-28
US20250213488A1 (en) 2025-07-03
NO2020015I1 (no) 2020-06-11
EP3632448B1 (en) 2022-01-12
SMT202000063T1 (it) 2020-03-13
SI3632448T1 (sl) 2022-04-29
EA201291372A1 (ru) 2013-06-28
BR112012033391A2 (pt) 2016-11-22
US11478487B1 (en) 2022-10-25
EA028680B1 (ru) 2017-12-29
EP3632448A1 (en) 2020-04-08
KR20130048227A (ko) 2013-05-09
CA3061421A1 (en) 2012-01-05
NO2022030I1 (no) 2022-07-11
CY1122544T1 (el) 2021-01-27
AU2011273605B2 (en) 2016-05-26
SI2588114T1 (sl) 2020-07-31
US11491113B1 (en) 2022-11-08
JP5810159B2 (ja) 2015-11-11
CY1125061T1 (el) 2023-06-09
SMT202200129T1 (it) 2022-05-12
DK3632448T3 (da) 2022-02-07
CA3061421C (en) 2021-06-01
BR112012033391A8 (pt) 2018-04-17
RS59826B1 (sr) 2020-02-28
US20220339107A1 (en) 2022-10-27
US12090231B2 (en) 2024-09-17
EP2588114B1 (en) 2019-12-25
US20230372248A1 (en) 2023-11-23

Similar Documents

Publication Publication Date Title
US11439598B2 (en) Synthetic progestogens and pharmaceutical compositions comprising the same
KR102539030B1 (ko) 드로스피레논을 포함하는 약학적 조성물 및 피임용 키트
US11413249B2 (en) Synthetic progestogens and pharmaceutical compositions comprising the same
KR102210982B1 (ko) 드로스피레논을 포함하는 약학적 조성물 및 피임용 키트
HK40080446A (en) Pharmaceutical composition comprising drospirenone and contraceptive kit
AU2011273605B8 (en) Pharmaceutical composition comprising drospirenone and contraceptive kit
HK40026911A (en) Pharmaceutical composition comprising drospirenone and contraceptive kit
HK40026911B (en) Pharmaceutical composition comprising drospirenone for use as a contraceptive
OA16285A (en) Pharmaceutical composition comprising drospirenone and contraceptive kit.

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210127

Application number text: 1020197017379

Filing date: 20190617

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210210

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210506

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20211126

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210506

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20211126

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20210702

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20220225

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20220127

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20211126

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20210702

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20210506

X601 Decision of rejection after re-examination
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20220429

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20220225

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20211126

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2022101000994

Request date: 20220429

J301 Trial decision

Free format text: TRIAL NUMBER: 2022101000994; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20220429

Effective date: 20230322

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20230322

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20220429

Decision date: 20230322

Appeal identifier: 2022101000994

PS0901 Examination by remand of revocation
GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

Patent event date: 20230413

Patent event code: PS07012S01D

Comment text: Decision to Grant Registration

Patent event date: 20230324

Patent event code: PS07011S01I

Comment text: Notice of Trial Decision (Remand of Revocation)

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230526

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230526

End annual number: 3

Start annual number: 1

PG1601 Publication of registration